Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020)

ABSTRACT Introduction: Hematopoietic progenitor kinase (HPK1), a serine/threonine kinase, which is primarily expressed in hematopoietic cells is a negative regulator of T-cell receptor and B cell signaling. Studies using genetic disruption of HPK1 function show enhanced T-cell signaling, cytokine production, and in vivo tumor growth inhibition. This profile of enhanced immune response highlights small molecule inhibition of HPK1 as an attractive approach for the immunotherapy of cancer. Areas covered: This article summarizes the biological rationale for the inhibition of HPK1 as a potential adjunct to the current immuno-oncology (IO) therapies. The article primarily discloses the current state of development of HPK1 inhibitors. Expert Opinion: The rapid increase in the identification of small molecule inhibitors of HPK1 should translate into a fuller understanding of the role of HPK1 inhibition in the IO setting. This understanding will be of huge importance in determining whether HPK1 inhibition alone will be sufficient for tumor growth inhibition or if combination with current IO therapies will be required.

• Publication year

  2021

• Venue

  Expert Opinion on Therapeutic Patents

• Publication date

  2021-05-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/13543776.2021.1924671PMID 33956554
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

  2021cited by this paper
• Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1

  2021cited by this paper
• Abstract 1947: Development and characterization of small molecule HPK1 inhibitors

  2020cited by this paper
• Development of High-Throughput Assays for Evaluation of Hematopoietic Progenitor Kinase 1 Inhibitors

  2020influential reference
• Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1).

  2020influential reference
• Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors.

  2020cited by this paper
• Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies.

  2020cited by this paper
• Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function

  2020cited by this paper
• Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology

  2019influential reference
• The Structure of HPK1 Kinase Domain: To Boldly Go Where No Immuno-Oncology Drugs Have Gone Before.

  2019cited by this paper
• Hematopoietic Progenitor Kinase-1 Structure in a Domain-Swapped Dimer.

  2019cited by this paper
• Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation

  2019cited by this paper
• GLK-IKKβ signaling induces dimerization and translocation of the AhR-RORγt complex in IL-17A induction and autoimmune disease

  2018cited by this paper
• The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function.

  2018cited by this paper
• Leading Edge Review Primary , Adaptive , and Acquired Resistance to Cancer Immunotherapy

  2017cited by this paper
• Germinal‐center kinase‐like kinase co‐crystal structure reveals a swapped activation loop and C‐terminal extension

  2017cited by this paper
• Small-Molecule Targets in Immuno-Oncology.

  2017cited by this paper
• METHODS FOR HUMAN T-CELL ACTIVATION

  2017cited by this paper
• Small molecule immuno-oncology therapeutic agents.

  2017cited by this paper
• MAP4K Family Kinases in Immunity and Inflammation.

  2016cited by this paper
• Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.

  2016cited by this paper
• The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

  2016cited by this paper
• Small-Molecule PROTACS: New Approaches to Protein Degradation.

  2016cited by this paper
• Methods and compositions for treating cancer using PD-1 axis antagonists and HPK1 antagonists

  2015cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• HPK1 as a novel target for cancer immunotherapy

  2012cited by this paper
• Release of serine/threonine-phosphorylated adaptors from signaling microclusters down-regulates T cell activation

  2011cited by this paper
• The kinase GLK controls autoimmunity and NF-κB signaling by activating the kinase PKC-θ in T cells

  2011cited by this paper
• Comprehensive analysis of kinase inhibitor selectivity

  2011cited by this paper
• Hematopoietic Progenitor Kinase 1 Is a Negative Regulator of Dendritic Cell Activation

  2009cited by this paper
• Phosphorylation of CARMA1 by HPK1 is critical for NF-κB activation in T cells

  2009cited by this paper
• Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response

  2009cited by this paper
• A novel pathway down-modulating T cell activation involves HPK-1–dependent recruitment of 14-3-3 proteins on SLP-76

  2007cited by this paper
• Chapter 2 – Cancer Immunoediting: From Immune Surveillance to Immune Escape

  2007cited by this paper
• Activation of Hematopoietic Progenitor Kinase 1 Involves Relocation, Autophosphorylation, and Transphosphorylation by Protein Kinase D1

  2005cited by this paper
• Src family kinases, key regulators of signal transduction

  2004cited by this paper
• Involvement of Hematopoietic Progenitor Kinase 1 in T Cell Receptor Signaling*

  2001cited by this paper
• Hematopoietic Progenitor Kinase 1 Associates Physically and Functionally with the Adaptor Proteins B Cell Linker Protein and SLP-76 in Lymphocytes*

  2001cited by this paper
• Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade.

  1996cited by this paper
• HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway.

  1996cited by this paper

• Targeting HPK1 for cancer immunotherapy: An update on recent medicinal chemistry advances.

  2026cites this paper
• Discovery of HDM2004, a potent, selective and orally bioavailable HPK1 inhibitor for tumor immunotherapy.

  2026cites this paper
• Discovery of highly selective and potent HPK1 inhibitors for cancer immunotherapy.

  2025cites this paper
• Targeting hematopoietic progenitor kinase 1 (HPK1) for tumor immunotherapy: advances in small molecule inhibitors.

  2025cites this paper
• Updated patent review for hematopoietic progenitor kinase (HPK1) inhibitors and degraders (2021-present)

  2025cites this paper
• Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade

  2025cites this paper
• Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitors.

  2025cites this paper
• Identification of Novel HPK1 Hit Inhibitors: From In Silico Design to In Vitro Validation

  2025cites this paper
• Application of a macrocyclization strategy in kinase inhibitor development

  2025cites this paper
• Research progress in bifunctional small molecules for cancer immunotherapy.

  2025cites this paper
• Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor.

  2025cites this paper
• Targeting HPK1 inhibits neutrophil responses to mitigate post-stroke lung and cerebral injuries

  2025cites this paper
• Rational design, optimization, and biological evaluation of novel pyrrolo-pyridone derivatives as potent and orally active Cbl-b inhibitors.

  2025cites this paper
• Design, synthesis, and pharmacological evaluation of novel isoindoline-based HPK1 degraders.

  2025cites this paper
• Targeting Cbl-b by a small molecular inhibitor potentiates T cell receptor signaling and suggests rational combination strategies.

  2025cites this paper
• Discovery of macrocyclic derivatives bearing N-sulfonyl-pyrazole moiety as new potent hematopoietic progenitor kinase 1 inhibitors.

  2025cites this paper
• Opportunities and challenges for targeting HPK1 in cancer immunotherapy.

  2024cites this paper
• Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b).

  2024cites this paper
• Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.

  2024cites this paper
• Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress

  2024cites this paper
• Macrocyclization strategy for improving candidate profiles in medicinal chemistry.

  2024cites this paper
• Tetrahydroisoquinolines – an updated patent review for cancer treatment (2016 – present)

  2024cites this paper
• Discovery of 1(2H)-phthalazinone and 1(2H)-isoquinolinone derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.

  2024cites this paper
• Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer

  2024cites this paper
• An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti-Solid Tumor Immunity.

  2024cites this paper
• An updated review of small-molecule HPK1 kinase inhibitors (2016-present).

  2024cites this paper
• Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer.

  2024cites this paper
• PROTACs: Novel tools for improving immunotherapy in cancer.

  2023cites this paper
• Small-molecule agents for cancer immunotherapy

  2023cites this paper
• Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling.

  2023cites this paper
• Discovery of potent and selective HPK1 inhibitors based on the 2,4-disubstituted pyrimidine scaffold with immune modulatory properties for ameliorating T cell exhaustion.

  2023cites this paper
• Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1.

  2023cites this paper
• Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets

  2023cites this paper
• An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma

  2023cites this paper
• Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.

  2023cites this paper
• The expanding role for small molecules in immuno-oncology

  2022cites this paper
• Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy.

  2022cites this paper
• Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors.

  2022cites this paper
• The development of small-molecule inhibitors targeting HPK1.

  2022cites this paper
• Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).

  2021cites this paper